Celldex Therapeutics (CLDX) Enterprise Value (2010 - 2026)
Celldex Therapeutics (CLDX) posted quarterly Enterprise Value of -$451.5 million for Q1 2026, up 32.95% year-over-year from -$339.6 million in Q1 2025, and up 12.94% quarter-over-quarter from -$518.6 million in Q4 2025.
Celldex Therapeutics (CLDX) Enterprise Value (2010 - 2026) Analysis & Trends
Celldex Therapeutics' Enterprise Value history runs 17 years deep, the most recent figure standing at -$451.5 million for Q1 2026.
- In Q1 2026, Enterprise Value rose 32.95% year-over-year to -$451.5 million; the TTM figure through Mar 2026 stood at -$451.5 million (up 32.95% YoY), while the FY2025 annual figure was -$518.6 million, up 28.5% from the prior year.
- Enterprise Value for Q1 2026 stood at -$451.5 million, up from -$518.6 million in the prior quarter.
- The five-year high for Enterprise Value was -$235.3 million in Q3 2023, with the low at -$823.8 million in Q1 2024.
- The 5-year median for Enterprise Value is -$451.5 million (2026), against an average of -$501.2 million.
- The sharpest annual moves came in 2024 and 2026: Enterprise Value plunged 221.23% in 2024, then jumped 32.95% in 2026.
- Celldex Therapeutics' Enterprise Value stood at -$305.0 million in 2022, then slumped by 38.91% to -$423.6 million in 2023, then sank by 71.22% to -$725.3 million in 2024, then rose by 28.5% to -$518.6 million in 2025, then gained by 12.94% to -$451.5 million in 2026.
- Business Quant data shows CLDX's Enterprise Value at -$451.5 million in Q1 2026, -$518.6 million in Q4 2025, and -$583.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Celldex Therapeutics | 3.29 Bn | 2.58 Bn | -2.57 Mn | -717.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -717.59 Mn |
| Mar 31, 2026 | -451.46 Mn |
| Dec 31, 2025 | -518.57 Mn |
| Sep 30, 2025 | -583.22 Mn |
| Jun 30, 2025 | -630.34 Mn |
| Mar 31, 2025 | -673.29 Mn |
| Dec 31, 2024 | -725.28 Mn |
| Sep 30, 2024 | -756.00 Mn |
| Jun 30, 2024 | -802.32 Mn |
| Mar 31, 2024 | -823.85 Mn |
| Dec 31, 2023 | -423.60 Mn |
| Sep 30, 2023 | -235.35 Mn |
| Jun 30, 2023 | -252.70 Mn |
| Mar 31, 2023 | -278.39 Mn |
| Dec 31, 2022 | -304.95 Mn |
| Sep 30, 2022 | -323.47 Mn |
| Jun 30, 2022 | -356.82 Mn |
| Mar 31, 2022 | -380.47 Mn |
| Dec 31, 2021 | -408.25 Mn |
| Sep 30, 2021 | -423.09 Mn |